via fool.com
End the practice of pharmaceutical companies paying other companies to delay launching generic versions of branded drugs. That's now the official position of the American Medical Association, which convened in Hawaii this week.
Want a second opinion? The Third Circuit Court of Appeals ruled in July that pay-for-delay arrangements are anti-competitive. The Federal Trade Commission has argued for over a decade that the practice is unfair and should be stopped. Congressional members from both major political parties have also spoken out against pay-for-delay deals.
No comments:
Post a Comment